Opinion: Like Tobacco, Cannabis Should Include a Warning Label — Especially for Suicide Risk

Cannabis products should carry a warning and consumer protections like tobacco and alcohol. One of the warnings is that the key ingredient THC has a risk of suicide.

That’s why Senate Bill 1097, the Cannabis Right to Know Act, is a step in the right direction for consumer protection.

California has not passed any consumer protection laws on the cannabis industry since Proposition 64 legalized marijuana. In contrast, Colorado passed public health protection on marijuana concentrates.

The act “requires the Colorado School of Public Health to do a systematic review of the scientific research related to the possible physical and mental health effects of high-potency THC marijuana and concentrates.”

National Institutes of Health study suggests a link between cannabis use and higher suicide ideation, plan and attempt levels. In short, there appears to be a vital link between cannabis use and suicide in young adults.

 

Read the full opinion piece by current IASIC Vice Present Roneet Lev here: https://timesofsandiego.com/opinion/2022/04/05/like-tobacco-cannabis-should-include-a-warning-label-especially-for-suicide-risk/

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents  Cannabis and Mental Health

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Placebo Effect a Major Driver of Pain Reduction in Cannabis Trials

A strong placebo response may be largely responsible for the significant pain reduction observed in clinical trials of cannabis-based therapies, results of a new meta-analysis suggest. Investigators found that while the effect size of cannabinoids on pain intensity was significant, the placebo effect was about the same. “The data from the present meta-analysis, including 1459

Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005–2019

Since 2005, diagnoses of cannabis use disorder have increased substantially among VHA patients, as they have in the general population and other patient populations. Possible explanations warranting investigation include decreasing perception of risk, changing laws, increasing cannabis potency, stressors related to growing socioeconomic inequality, and use of cannabis to self-treat pain. Clinicians and the public

Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado

The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado. This was a retrospective cohort study of pregnancy-related hospitalizations co-coded with cannabis diagnosis codes in the Colorado Hospital Association from January 1, 2011, through December 31, 2018 (recreational cannabis began

Scroll to Top